Free Newsletter
MIT computer model designs better therapies
Researchers at MIT have developed a computer model which they say can rev up the effectiveness of an antibody-based therapy. And it's not just a theory. They say that they have used the model to design a new form of cetuximab (Erbitux)--a therapy for colorectal cancer--that is 10 times better at binding to its target than the original molecule. The model reviews potential amino-acid substitutions, looking for ways to build a structure with greater binding properties. The scientists say that better protein modeling can also reduce the cost of developing the drugs.
"New and better methods for improving antibody development represent critical technologies for medicine and biotechnology," says MIT Professor Dane Wittrup.
- see this release from MIT
- here's a report on the new model
Related Articles:
Universities, public institutes lead biotech revolution. Report
Computer advances allow new methods of protein analysis. Report
Universities create cardiac data grid. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment